IP Library Granted Patent US 11,459,376
Granted Patent B2
US 11,459,376 · App. 17/351,963 · Granted Oct 4, 2022

Compositions and methods for the delivery of therapeutic biologics for treatment of disease

Inventors: Paul Brown (Boston, MA); Tyler L. Carter (Newburyport, MA); Lyndon Fitzgerald Charles, Jr. (Medford, MA); Chase Spenser Coffman (Newton, MA); Daniel Benjamin Dadon (East Boston, MA); Lisa Liu (Somerville, MA); Sadiqua Shadbar (Allston, MA); Chaitanya Sudrik (Stoneham, MA); Yi Tang (Medford, MA); Shankul Vartak (Cambridge, MA)
Assignee: Elektrofi, Inc.
C07K16/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,459,376
App. No.
17/351,963
Granted
Oct 4, 2022
Kind
B2
Abstract

The present disclosure provides compositions and methods for treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising a plurality of particles comprising at least one therapeutic biologic suspended in a pharmaceutically acceptable liquid carrier.

Claims (18)

1. A pharmaceutically effective non-aqueous composition comprising particles: wherein a plurality of the particles in the composition are suspended in an organic solvent carrier and comprise at least one antibody or a fragment thereof, wherein each particle that comprises at least one antibody or a fragment thereof has less than 10% internal void space and greater than 70% antibody or fragment thereof by weight; wherein: the particles have less than 3% aggregation of the antibody or fragment thereof; and the concentration of the antibody or fragment thereof in the composition is from 400 mg/mL to 650 mg/mL.

2. The composition of claim 1 , wherein the particles have less than 3% change in charge variants of the antibody or fragment thereof.

3. The composition of claim 1 , wherein the particles have a circularity from 0.80 to about 1.00.

4. The composition of claim 1 , wherein the particles have less than 3% residual moisture by weight.

5. The composition of claim 1 , wherein each particle has less than 5% internal void space.

6. The composition of claim 1 , wherein each particle has less than 1% internal void space.

7. The composition of claim 1 , wherein each particle is free from any internal void space.

8. The composition of claim 1 , wherein the particles have greater than 80% antibody or fragment thereof by weight.

9. The composition of claim 1 , wherein the particles further comprise a carbohydrate, a pH adjusting agent, a salt, a chelator, a mineral, a polymer, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a protein, an organic solvent, a paraben, a bactericide, a fungicide, a vitamin, a preservative, a nutrient media, analgesic, or a combination thereof.

10. The composition of claim 1 , wherein the composition has a viscosity of less than 100 mPaS.

11. The composition of claim 1 , wherein the composition is free of insoluble Subvisible Particles (SvPs) upon dissolution in water.

12. The composition of claim 1 , wherein the composition upon dissolution in water has a turbidity that differs from the turbidity of an aqueous composition comprising the antibody or a fragment thereof, by less than 0.1 FTU.

13. The composition of claim 1 , wherein the composition has no change in immunogenicity compared to an aqueous composition comprising the antibody or fragment thereof.

14. The composition of claim 1 , wherein the composition is non-immunogenic.

15. The composition of claim 1 , wherein the composition has no change in toxicity compared to an aqueous composition comprising the antibody or fragment thereof.

16. The composition of claim 1 , wherein the composition is non-toxic.

17. The composition of claim 1 , wherein the antibody or fragment thereof in the composition is stable for at least three months.

18. The composition of claim 1 , wherein the antibody or fragment thereof in the composition is stable for at least three months at 40° C.

Assignments (2)
CHANGE OF NAME Recorded Feb 2, 2026
From: ELEKTROFI, INC.
To: HALOZYME HYPERCON, INC.
Reel/Frame 073662/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2021
From: BROWN, PAUL; CARTER, TYLER L.; CHARLES, LYNDON FITZGERALD, JR.; COFFMAN, CHASE SPENSER; DADON, DANIEL BENJAMIN; LIU, LISA; SHADBAR, SADIQUA; SUDRIK, CHAITANYA; TANG, YI; VARTAK, SHANKUL
To: ELEKTROFI, INC.
Reel/Frame 057922/0500 →
Continuity (5)
Continuation PCTUS2020050508 · Sep 11, 2020
Provisional Application 63024703 · May 14, 2020
Provisional Application 62899907 · Sep 13, 2019
Provisional Application 62899981 · Sep 13, 2019
Related Publication 20210309724A1 · Oct 7, 2021
Cited By (7)
US 12,263,249 US 12,263,253 US 12,377,050 US 12,433,849 US 12,558,323 US 12,569,445 US 12,600,763